Since nuclear factor of κ‐light chain of enhancer‐activated B cells (NF‐κB) was discovered
in 1986, extraordinary efforts have been made to understand the function and regulating …

Ribosome biogenesis and protein synthesis are fundamental rate-limiting steps for cell
growth and proliferation. The ribosomal proteins (RPs), comprising the structural parts of the …

The development of precision medicine approaches for diffuse large B cell lymphoma
(DLBCL) is confounded by its pronounced genetic, phenotypic, and clinical heterogeneity …

Ribosomes are a complex ensemble of rRNA and ribosomal proteins that function as mRNA
translation machines. Ribosome biogenesis is a multistep process that begins in the …

Chronic lymphocytic leukaemia (CLL), the most frequent type of leukaemia in adults, is a
lymphoproliferative disorder that is characterized by the expansion of monoclonal, mature …

Resistance to the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has been attributed solely
to mutations in BTK and related pathway molecules. Using whole-exome and deep-targeted …

Ribosomopathies are diseases caused by defects in ribosomal constituents or in factors with
a role in ribosome assembly. Intriguingly, congenital ribosomopathies display a paradoxical …

Chronic lymphocytic leukaemia (CLL) is a malignancy of CD5+ B cells that is characterized
by the accumulation of small, mature-appearing lymphocytes in the blood, marrow and …

Chronic lymphocytic leukemia is associated with a highly heterogeneous disease course in
terms of clinical outcomes and responses to chemoimmunotherapy. This heterogeneity is …

Genetic parameters are established prognostic factors in chronic lymphocytic leukemia
(CLL) treated with chemoimmunotherapy, but are less well studied with novel compounds …